SLS vs. AUP, BHC, CARA, CRON, TEV, ABT, NOT, PYR, NVO, and DNA
Should you be buying Solaris Resources stock or one of its competitors? The main competitors of Solaris Resources include Aurinia Pharmaceuticals (AUP), Bausch Health Companies (BHC), Cara Operations (CARA), Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), and Dalradian Resources (DNA). These companies are all part of the "pharmaceutical products" industry.
Solaris Resources vs.
Solaris Resources (TSE:SLS) and Aurinia Pharmaceuticals (TSE:AUP) are both basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Solaris Resources presently has a consensus price target of C$13.90, indicating a potential upside of 137.61%. Given Solaris Resources' stronger consensus rating and higher probable upside, equities analysts plainly believe Solaris Resources is more favorable than Aurinia Pharmaceuticals.
25.1% of Solaris Resources shares are held by institutional investors. 40.6% of Solaris Resources shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Aurinia Pharmaceuticals' return on equity of 0.00% beat Solaris Resources' return on equity.
In the previous week, Solaris Resources had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 4 mentions for Solaris Resources and 0 mentions for Aurinia Pharmaceuticals. Solaris Resources' average media sentiment score of 0.41 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Solaris Resources is being referred to more favorably in the media.
Solaris Resources has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Solaris Resources is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals received 232 more outperform votes than Solaris Resources when rated by MarketBeat users. Likewise, 72.22% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave Solaris Resources an outperform vote.
Summary
Solaris Resources beats Aurinia Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Solaris Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solaris Resources Competitors List
Related Companies and Tools
This page (TSE:SLS) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SLS Stock Free SLS Stock Alerts